Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof
Summary
USPTO published patent application US20260092055A1 by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives useful as LpxC inhibitors for treating bacterial infections. The application covers the chemical compounds, preparation methods, and pharmaceutical compositions. Application No. 19112826 was filed September 28, 2023.
What changed
USPTO published patent application US20260092055A1 filed by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives represented by general formula (I) and their use as LpxC (lipid A biosynthesis enzyme) inhibitors. The compounds are intended for antibacterial therapeutic applications. Inventors include Xiangui Huang, Weiwei Liao, Chengfei Wu, Cheng Ye, Daiwang Xu, Xu Xiaojie, and Houjiang Zhou.
Entities engaged in LpxC inhibitor research, antibacterial drug development, or related pharmaceutical manufacturing should review this application for potential freedom-to-operate concerns or licensing opportunities. Patent applications do not create immediate compliance obligations but establish prior art that may affect future patent prosecution in this technological space.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof
Application US20260092055A1 Kind: A1 Apr 02, 2026
Assignee
Zhejiang Hisun Pharmaceutical Co., Ltd.
Inventors
Xiangui Huang, Weiwei LIAO, Chengfei WU, Cheng YE, Daiwang XU, XU Xiaojie, Houjiang ZHOU
Abstract
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and pharmaceutical use of a pharmaceutical composition comprising the derivative. Specifically, the present invention relates to an aromatic acetylene derivative represented by general formula (I), a preparation method therefor, a pharmaceutically acceptable salt thereof, and use thereof as a therapeutic agent, particularly as an LPXC inhibitor, wherein the definitions of the substituents in general formula (I) are the same as those in the specification.
CPC Classifications
C07D 413/14 A61K 31/422 A61K 31/4439 A61K 31/454 A61K 31/496 A61K 31/5377 A61P 31/04 C07D 413/06
Filing Date
2023-09-28
Application No.
19112826
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.